"The Company will continue to assess the probability of milestone payments throughout the180-day right of first negotiation period".
What insights are available into what TCRX might have discovered during the Novartis collaboration period, and to whom would these TCR targets be of concern/value to? And to what monetary value are such TCR discoveries worth/to Novartis/others.
Deadline for the 180-day right of first negotiation period, in and around September 28 by my count.
Given the Amgen news came out, out of nowhere, so to, could news on licensing/Novartis come out anytime to Sept.28/23.
Market Data 
Markets 
AI
